164 related articles for article (PubMed ID: 36708787)
1. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
[TBL] [Abstract][Full Text] [Related]
2. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
Deek MP; Sutera P; Jing Y; Gao R; Rothman E; Day H; Chang D; Dirix P; Armstrong AJ; Campbell B; Campos FL; Berenguer M; Ramotar M; Conde-Moreno A; Berlin A; Bosetti DG; Corcoran N; Koontz B; Mercier C; Siva S; Pryor D; Ost P; Huynh MA; Kroeze S; Stish B; Kiess A; Trock B; Tran PT; Gillessen S; Sweeney C
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38570239
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
Sutera P; Song Y; Van der Eecken K; Shetty AC; English K; Hodges T; Chang J; Fonteyne V; Rana Z; Ren L; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Song DY; Pienta K; Feng FY; Joniau S; Lotan T; Lane B; Kiess A; Rowe S; Pomper M; DeWeese T; Deek M; Sweeney C; Ost P; Tran PT
Eur Urol; 2023 Dec; 84(6):531-535. PubMed ID: 37173210
[TBL] [Abstract][Full Text] [Related]
4. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
5. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
Deek MP; Van der Eecken K; Phillips R; Parikh NR; Isaacsson Velho P; Lotan TL; Kishan AU; Maurer T; ; Boutros PC; Hovens C; Abramowtiz M; Pollack A; Desai N; Stish B; Feng FY; Eisenberger M; Carducci M; Pienta KJ; Markowski M; Paller CJ; Antonarakis ES; Berlin A; Ost P; Tran PT
Eur Urol; 2021 Nov; 80(5):632-640. PubMed ID: 33419682
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.
Deek MP; Taparra K; Dao D; Chan L; Phillips R; Gao RW; Kwon ED; Deville C; Song DY; Greco S; Carducci MA; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Stish BJ; Tran PT
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):387-395. PubMed ID: 32798608
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Deek MP; Van der Eecken K; Sutera P; Deek RA; Fonteyne V; Mendes AA; Decaestecker K; Kiess AP; Lumen N; Phillips R; De Bruycker A; Mishra M; Rana Z; Molitoris J; Lambert B; Delrue L; Wang H; Lowe K; Verbeke S; Van Dorpe J; Bultijnck R; Villeirs G; De Man K; Ameye F; Song DY; DeWeese T; Paller CJ; Feng FY; Wyatt A; Pienta KJ; Diehn M; Bentzen SM; Joniau S; Vanhaverbeke F; De Meerleer G; Antonarakis ES; Lotan TL; Berlin A; Siva S; Ost P; Tran PT
J Clin Oncol; 2022 Oct; 40(29):3377-3382. PubMed ID: 36001857
[No Abstract] [Full Text] [Related]
8. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
Sutera PA; Shetty AC; Hakansson A; Van der Eecken K; Song Y; Liu Y; Chang J; Fonteyne V; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Rana Z; Hodges T; Hamid A; Roberts N; Song DY; Pienta K; Ross AE; Feng F; Joniau S; Spratt D; Gillessen S; Attard G; James ND; Lotan T; Davicioni E; Sweeney C; Tran PT; Deek MP; Ost P
Ann Oncol; 2023 Jul; 34(7):605-614. PubMed ID: 37164128
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
Sutera P; Shetty AC; Song Y; Hodges T; Hoang T; Rana Z; Pienta K; Feng F; Song DY; DeWeese T; Gillessen S; Sweeney C; James N; Attard G; Deek M; Tran PT
Eur Urol Oncol; 2024 Apr; 7(2):241-247. PubMed ID: 37558543
[TBL] [Abstract][Full Text] [Related]
12. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
Hoang T; Sutera P; Nguyen T; Chang J; Jagtap S; Song Y; Shetty AC; Chowdhury DD; Chan A; Carrieri FA; Hathout L; Ennis R; Jabbour SK; Parikh R; Molitoris J; Song DY; DeWeese T; Marchionni L; Ren L; Sawant A; Simone N; Lafargue A; Van Der Eecken K; Bunz F; Ost P; Tran PT; Deek MP
Prostate; 2024 Jan; 84(1):87-99. PubMed ID: 37812042
[TBL] [Abstract][Full Text] [Related]
13. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
Onal C; Ozyigit G; Akgun Z; Atalar B; Igdem S; Oymak E; Agaoglu F; Selek U; Guler OC; Hurmuz P; Mustafayev TZ; Akyol F
Clin Nucl Med; 2021 Jun; 46(6):465-470. PubMed ID: 33661210
[TBL] [Abstract][Full Text] [Related]
14. [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?].
Steuber T; Maurer T; Miller K
Urologe A; 2021 Dec; 60(12):1534-1545. PubMed ID: 34734294
[TBL] [Abstract][Full Text] [Related]
15. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38182487
[TBL] [Abstract][Full Text] [Related]
16. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
17. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
20. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
Melucci E; Casini B; Ronchetti L; Pizzuti L; Sperati F; Pallocca M; De Nicola F; Goeman F; Gallo E; Amoreo CA; Sergi D; Terrenato I; Vici P; Di Lauro L; Diodoro MG; Pescarmona E; Barba M; Mazzotta M; Mottolese M; Fanciulli M; Ciliberto G; De Maria R; Buglioni S; Maugeri-Saccà M
J Transl Med; 2018 Feb; 16(1):22. PubMed ID: 29402328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
